Gene Therapy

Gene Therapy is published by Springer Nature and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Virus-based gene therapy research, RNA Interference and Gene Delivery and CRISPR and Genetic Engineering, together about 52.5% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)

Gene Therapy covers both the research and clinical applications of novel therapeutic techniques based on a genetic component. Over the last few decades, significant advances in technologies ranging from identifying novel genetic targets that cause disease through to clinical studies, which show therapeutic benefit, have elevated this multidisciplinary field to the forefront of modern medicine. Gene Therapy covers all aspects of gene therapy as applied to human disease, including: preliminary studies which reveal novel genetic targets or strategies that improve a disease phenotype (Note: studies showing the mechanistic role of genetic elements alone, will be considered if significant therapeutic benefit or novelty is shown) the development of novel techniques for gene therapy research and improvements on established tools preclinical animal model systems and validation studies gene-based vaccine development and applications genetically engineered cellular models that can advance the validation of novel therapeutic targets, and drug discovery especially those using high-throughput applications and 3D modelling cell-based therapies including all aspects of stem cells and genetically modified cellular approaches (especially CRISPR and other gene editing strategies), including biobanking studies clinical trial reports which have significant impact for the field novel genetic biomarkers of disease susceptibility or disease progression with extensive scientific validation Industry sector pipeline profiles or commercial implications of gene therapies Regulatory landscapes and legislative issues pertaining to different global regions

From the journal's Aims & Scope

Research area (LetPub): Biochemistry & Molecular Biology

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

MEDLINECurrent ContentsPublisher website

Other: Google Scholar, EBSCO, ProQuest, BIOSIS, EBSCO Discovery Service, Social Science Citation Indes, Summon by ProQuest, EBSCO Academic Search, EBSCO Advanced Placement Source, EBSCO Biomedical Reference Collection, EBSCO STM Source, EBSCO TOC Premier

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

5.83LetPub · 2026-09-13

Impact factor (publisher) 2025

5.9Publisher website · 2026-09-29

5-year impact factor (publisher) 2025

5.4Publisher website · 2026-09-29

CiteScore 2026-06

10.1LetPub · 2026-09-13

SJR 2026-06

1.5LetPub · 2026-09-13

SNIP 2026-06

1.13LetPub · 2026-09-13

h-index

153LetPub · 2026-09-13

h-index

193OpenAlex · 2026-10-01

i10-index

3,887OpenAlex · 2026-10-01

2-year mean citedness

4.39OpenAlex · 2026-10-01

Self-citation rate

3.4%LetPub · 2026-09-13

Share of gold OA articles

52.41%LetPub · 2026-09-13

Volume

Articles per year

64LetPub · 2026-09-13

Downloads per year (publisher) 2025

1,605,432Publisher website · 2026-09-29

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

4–8 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly hardLetPub · 2026-09-13

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Springer Nature

Country or region

ENGLAND

Language

English

Frequency

Semimonthly

Founded

1997

ISSN

0969-7128

Electronic ISSN

1476-5462

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Author guidelines ↗LetPub
• Special issues ↗Publisher website